MIG Capital invests in Munich-based microbiome therapeutics developer mbiomics GmbH in an A-round financing. The biotech company uses its customized, high-precision bacterial profiling platform to accelerate the development of effective microbiome-based therapeutics. The consortium led by MIG also includes High-Tech Gründerfond, Bayern Kapital and private seed investors. The funding will enable mbiomics to expand its platform, enter strategic partnerships and expand its R&D teams and infrastructure.
MIG Capital AG, one of Germany’s leading venture capital firms, announced today that it is investing in mbiomics GmbH as part of a first closing of a €13 million Series A round. The pioneering microbiome biotech company based in Munich, Germany, is developing the first generation of effective microbiome-based therapeutics. mbiomics uses its proprietary high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation.
The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision therapies. mbiomics’ core technology also improves patient selection and monitoring for clinical trials, and thus creates a competitive edge.
The financing was led by MIG, with participation from High-Tech Gründerfonds and Bayern Kapital alongside a pool of private seed investors. mbiomics will use the proceeds to embark on strategic partnerships, significantly expand its Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.
“We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies,” said Dr. Laura Figulla, co-founder and CEO of mbiomics. “This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.”
With the announced closing, mbiomics is in a position to spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases.
Dr. Matthias Kromayer, Managing Partner of MIG Capital, commented: “We are delighted to announce our investment in mbiomics and to back its journey to develop a truly innovative therapeutics platform. The company’s leading-edge approach of combining emerging technologies with the most advanced microbiome research has the potential to significantly improve patient outcomes. We look forward to supporting its ongoing research towards clinical development.”